Travere Therapeutics price target raised to $45 from $41 at Guggenheim

Guggenheim raised the firm’s price target on Travere Therapeutics (TVTX) to $45 from $41 and keeps a Buy rating on the shares. The company’s “strong” Q4 performance underscores patient demand, physician comfort, and commercial excellence, the analyst tells investors in a research note. The firm is “increasingly optimistic” about the near- and long-term potential for Filspari. It continues to view Travere as its “Best Idea.”